Pharmaceutical

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Aug 1, 2024 - 04:00
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Read the original article

Tags:

Previous Article

Magazine: Left in limbo: when pharma halts rare disease research

Next Article

Imunon’s shares soar after IL-12 therapy success in Phase II trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

STAT+: U.K. sequencing study surfaces new findings abou...

Jan 10, 2024

Opinion: Every smartphone should have an app to connect to 988, the mental health crisis line

Opinion: Every smartphone should have an app to connect...

Sep 22, 2023

ConSynance wins FDA designation for Prader-Willi syndrome therapy

ConSynance wins FDA designation for Prader-Willi syndro...

Jul 26, 2024